Skip to content

A Multicenter Study to Evaluate the ROX Arteriovenous Coupler in Patients With Treatment-Resistant Hypertension

ROX CONTROL HTN Study: A Prospective, Randomized, Open-Label, Multicenter Study to Evaluate the ROX Coupler in Patients With Resistant Hypertension

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01642498
Enrollment
100
Registered
2012-07-17
Start date
2012-09-01
Completion date
2018-06-30
Last updated
2019-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

High Blood Pressure, Hypertension, Resistant Hypertension

Brief summary

The purpose of this study is to evaluate the safety and performance of the ROX COUPLER in patients with treatment-resistant hypertension.

Interventions

The COUPLER will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).

Sponsors

ROX Medical, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of treatment-resistant hypertension must be made on the basis of current findings, medical history, and physical examination

Exclusion criteria

* Any serious medical condition that may adversely affect the patient's safety, limit the subject's ability to participate in the study, comply with follow-up requirements or impact the scientific integrity of the study.

Design outcomes

Primary

MeasureTime frameDescription
Change in mean office SBPBaseline, 6 monthsChange in mean office SBP at six months as compared to Baseline

Secondary

MeasureTime frameDescription
Change in mean office DBPBaseline, 6 monthsChange in mean office DBP at six months as compared to Baseline

Countries

Belgium, Germany, Greece, Ireland, Netherlands, Poland, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026